CS-917, a fructose 1,6-bisphosphatase inhibitor, combined with a thiazolidinedione or insulin decreases plasma glucose and improves lactate metabolism more effectively than CS-917 monotherapy

被引：0
|
作者：
Yoshida, T. [1 ]
Ogawa, J. [1 ]
Hagisawa, Y. [1 ]
Kanda, S. [1 ]
Takahashi, K. [1 ]
Okuno, A. [1 ]
机构：
[1] Daiichi Sankyo Co, Biol Res Labs 2, Tokyo, Japan
来源：
DIABETOLOGIA | 2007年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0910
引用
收藏
页码：S375 / S375
页数：1
相关论文
共 14 条
  • [1] Comparative effects of CS-917, a fructose 1,6-bisphosphatase inhibitor, and metformin
    Okuno, A.
    Yoshida, T.
    Tanaka, J.
    Takahashi, K.
    Kanda, S.
    Nakashima, R.
    Ogawa, J.
    Hagisawa, Y.
    DIABETOLOGIA, 2006, 49 : 132 - 132
  • [2] CS-917, a fructose 1,6-bisphosphatase inhibitor, suppresses gluconeogenesis in vitro and in vivo by a different mechanism than metformin
    Okuno, Akira
    Tanaka, Jun
    Takahashi, Kanako
    Nakashima, Ryutaro
    Kanda, Shoichi
    Ogawa, Junko
    Hagisawa, Yuka
    Yoshida, Taishi
    DIABETES, 2006, 55 : A128 - A129
  • [3] Enhancement of insulin signaling suppresses lactate elevation induced by CS-917, a fructose 1,6-bisphosphatase (F1,6-BPase) inhibitor
    Yoshida, Taishi
    Ogawa, Junko
    Hagisawa, Yuka
    Kanda, Shoichi
    Takahashi, Kanako
    Okuno, Akira
    DIABETES, 2007, 56 : A131 - A131
  • [4] The fructose-1,6-bisphosphatase inhibitor CS-917 generates an N-acetylated metabolite that alters cellular lactate homeostasis
    van Poelje, P. D.
    Potter, S. C.
    Hou, J.
    Stebbins, J. W.
    Hecker, S. J.
    Erion, M. D.
    DIABETOLOGIA, 2009, 52 : S343 - S343
  • [5] CS-917, a fructose 1,6-bisphosphatase inhibitor, reduces plasma glucose by suppressing hepatic glucose production, whereas metformin stimulates gastrointestinal glucose uptake
    Okuno, A.
    Tanaka, J.
    Takahashi, K.
    Ogawa, J.
    Hagisawa, Y.
    Kanda, S.
    Yoshida, T.
    DIABETOLOGIA, 2007, 50 : S95 - S95
  • [6] Initial safety, tolerability and glucose lowering of CS-917, a novel fructose 1,6-bisphosphatase (FBPase) inhibitor, in subjects with type 2 diabetes
    Bruce, S. R.
    Walker, J.
    Feins, K.
    Tao, B.
    Triscari, J.
    DIABETOLOGIA, 2006, 49 : 25 - 25
  • [7] MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes
    Erion, MD
    van Poelje, PD
    Dang, Q
    Kasibhatla, SR
    Potter, SC
    Reddy, MR
    Reddy, KR
    Jiang, T
    Lipscomb, WN
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (22) : 7970 - 7975
  • [8] Comparison of acute and chronic glucose-lowering effect of CS-917, a fructose 1,6-bisphosphatase inhibitor, and metformin, in rat models of type 2 diabetes
    Yoshida, Taishi
    Takahashi, Kanako
    Nakashima, Ryutaro
    Kanda, Shoichi
    Okuno, Akira
    DIABETES, 2006, 55 : A139 - A139
  • [9] Pharmacokinetics and pharmacodynamics of single-dose CS-917, a novel prodrug of a fructose 1,6-bisphosphatase inhibitor, in patients with type 2 diabetes
    Walker, Joseph R.
    Triscari, Joseph
    Freudenthaler, Stefan
    Golor, George
    Dmuchowski, Carl F.
    Naozumi, Samata
    Kaneko, Tsugio
    Bruce, Simon R.
    DIABETES, 2007, 56 : A551 - A551
  • [10] CS-917, a fructose 1,6-bisphosphatase inhibitor, has glucose-lowering effects in cynomolgus monkeys and improves postprandial hyperglycemia in goto-kakizaki (GK) rats
    Yoshida, T
    Izumi, M
    Takahashi, K
    Hagisawa, Y
    Ohsumi, J
    Fujiwara, T
    Okuno, A
    DIABETES, 2005, 54 : A116 - A117
12